FierceBiotech Names Vivet Therapeutics as One of Its 2017 “Fierce 15” Biotech Companies
Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Tuesday September 26th in Boston, MA.
Vivet Therapeutics is a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases.
“Vivet Team is honored to be selected as a Fierce 15 company," said Jean-Philippe COMBAL, CEO of Vivet Therapeutics. “Our world-class team combined with best-in-class science will allow us to develop life-changing treatments for rare inherited metabolic liver disorders while addressing key challenges of gene therapy, including sustained therapeutic gene expression in young patients, adults and immune responses towards the viral vector.”
Vivet Therapeutics is committed to make a significant difference for patients facing rare metabolic diseases. Vivet has a strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, University of Navarra, Spain), a leading research organization in the field of Gene Therapy. Vivet also has licensed the use of novel proprietary AAV vector gene therapy technology to treat metabolic diseases and certain patent-protected Anc80 AAV gene therapy vectors from Massachusetts Eye and Ear (MEE), a teaching hospital of Harvard Medical School, Boston. Anc80 is a next-generation gene therapy technology designed to increase gene expression levels in the liver.
“We will initiate clinical development of our lead product, VTX-801 for Wilson’s Disease, in Q4 2018 and already have 3 additional programs under preclinical development,” stated Jean-Philippe Combal. “Our entire team is committed to advancing our programs to generate transformative therapies for patients with high unmet medical needs.”
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's fifteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online.
For more information, visit www.vivet-therapeutics.com.
About VTX-801: VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper metabolism through liver cell targeting.
About FierceBiotech: FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Vivet Therapeutics: Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy products for inherited liver disorders with high medical need.
Media & Investors:
Thomas Daniel, +33 6 68 88 38 60
Business Development Director
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Pharnext to Announce Top-Line Results from the Pivotal Phase 3 Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Type 1A Disease by October 201821.6.2018 21:23 | Tiedote
Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018. Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s Co-Founder and Chief Executive Officer said: “We are thrilled to bring this Phase 3 clinical trial to completion and we now expect to disclose top-line results by October of this year. Our PLEODRUG™ PXT3003 has already shown initial signals of efficacy in our Phase 2 trial in CMT1A. We are hopeful we can bring this much-needed therapy to patients suffering from this debilitating condition, as they currently have limited therapeutic options, mo
Philip Morris International Makes Call to Creative, Media and Communications Communities21.6.2018 21:13 | Tiedote
Philip Morris International Inc. (“PMI”) (NYSE: PM), today announced a bold call to action for the creative, media and communications communities to embrace its ongoing commitment to creating a smoke-free world. As part of this initiative, PMI will offer smoke-free alternatives wherever we can, including heated tobacco products and e-cigarettes, to current smokers in the industry who would otherwise continue to smoke. During a keynote at the PMI Science Lounge at The Cannes Festival of Creativity, SVP of Communications Marian Salzman said, “We are asking the creative community to join us in raising awareness of the potential of science, technology and innovation for those who smoke and the people around them.” The move is part of PMI’s vision to lead the charge towards greater innovation and technology in the tobacco industry, all of which is backed by science. Agencies interested in joining the movement can contact Marian Salzman at firstname.lastname@example.org. “People who smoke deserve in
IBC2018 Announces Cyber Security Forum to Help Media Tackle Cyber Threats21.6.2018 19:30 | Tiedote
IBC2018, the world’s most influential media, entertainment and technology show, today announces a Cyber Security Forum to expand its position as the preeminent cyber security destination for broadcasters and media. The event will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018, which last year attracted more than 57,000 attendees from 170 countries. The Cyber Security Forum is one-day, invitation-only event that will convene Chief Technology Officers, Chief Information Officers, Chief Information Security Officers and Chief Digital Officers within media and broadcasting for a conversation on the challenges and opportunities presented by cyber security for broadcasters. Attendees will discuss how to anticipate the next cyber threat, how to manage a breach and how to prepare for the future of cyber security. The Cyber Security Forum sits alongside the Telco & Media Innovation Forum and Leaders’ Forum as part of IBC’s Exec
Mensia Technologies Raises 1,3 Million Euro to Introduce Koala Neurofeedback as a Revolutionary Medical Device in Europe21.6.2018 19:23 | Tiedote
Mensia Technologies, french MedTech start up, leads the new booming category of Digital therapeutics with its revolutionary « at home « neurofeedback, to train the brain and cure neuropsy disorders without drugs. Co-founder INRIA-IT2, existing shareholders and now HARA, which are business angels experts in medical device category, joined this fund raise. BPI de Rennes is also part of this tour. Mensia Technologies, borned out of INRIA in 2012. The IT expert labs in Rennes are computing real time signaling softwares. The neurofeedback technique is non invasive, at home and without drugs. MENSIA KOALA treats ADHD, Attention Deficit Disorders with or without Hyperactivity, children and adolescents. This unique medical device is a therapeutic video game on an interactive tablet connected to the brain activity. Children learn to control their attention by exercising 3 times a week during 4 months of treatment. Visual feedback given during the game, allows the children to learn, control and
Phlexglobal to Improve eTMF Document Transfers with Adoption of New Exchange Mechanism Standard21.6.2018 19:16 | Tiedote
Phlexglobal, a specialist provider of technology-enabled Trial Master File (TMF & eTMF) management solutions, is adopting Version 1 of the eTMF Exchange Mechanism Standard (eTMF-EMS) of the TMF Reference Model (TMF-RM) into PhlexEview, the company’s eTMF technology. This marks a major advancement in efficient document interchange and will firmly solidify Phlexglobal’s position as a driving force in eTMF management for clinical trials. Prior to the creation of the TMF Reference Model, there was no universal methodology for the organization of trial data in an eTMF. In 2009 Phlexglobal joined other industry TMF experts to create the TMF Reference Model which has primarily focused on organizing the artifacts of a clinical trial. While the TMF-RM has aided in the organization of artifact, the transfer of TMF to trial sponsors or contract research organizations has often required a significant amount of mapping and manipulation. Phlexglobal has extensive experience migrating millions of TMF
IDEMIA: Enter the World of Augmented Identity at our Pop-up Innovation Center in London (25th-27th June 2018)21.6.2018 17:36 | Tiedote
IDEMIA, the global leader in Augmented Identity, is announcing the opening of its Pop-up Innovation Center, at the heart of London, in Westminster (“Queen Elizabeth II Center”). It will take place from 25th to 27th of June, 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005800/en/ IDEMIA’s ambition is to enable a secure and trusted environment for citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel, vote or access public or private spaces), in the real as well as digital worlds. Opening its unique Pop-up Innovation Center, IDEMIA invites you to experience its innovative solutions through dedicated demonstration areas. IDEMIA will showcase a wide range of innovations, such as: Identity on the move: secure biometric systems to manage the flow of people The mobile generation: a new solution to put your ID in your smartphone, in a safe way - under your control and wit
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme